This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Antibody Engineering & Therapeutics Europe

ONLINE REGISTRATION CLOSES IN:

  • 00
    DAYS
  • 00
    HRS
  • 00
    MINS
  • 00
    SECS
Delivered as a Hybrid Event, 7 - 9 June, 2022
Live In-Person Event: 7 - 9 June, Postillion Hotel AmsterdamDigital Experience: All Sessions Livestreamed 7 - 9 June

Jack Lin, Ph.D.
Senior Director, New Technologies at Harpoon Therapeutics

Profile

Jack is currently a Sr. Director at Harpoon Therapeutics, where he and his team are focused on developing new T cell engager prodrugs and advancing Harpoon’s lead protease-activated T cell engager program, HPN601, from idea to IND. Before joining Harpoon, Jack was at CytomX developing protease-activated antibody drug conjugates and was an antibody engineer at Pfizer. He obtained his BS from the University of Toronto, PhD from Northwestern University, and was a postdoctoral research fellow at Genentech.

Agenda Sessions

  • Developing Protease-Activated T Cell Engager Prodrugs with Improved Spatial and Temporal Controls

    16:25